Highlightll Pharma

Hangzhou, China · Founded 2017 · In IPO Registration

Developer of a drug development approach designed to create therapies for autoimmune and inflammatory diseases affecting systemic and central nervous system conditions. Highlightll Pharma is based in Hangzhou, China and was founded in 2017. Its last reported valuation was $346 million in Nov 2025. It has raised $97.3 million.

Last reported valuation
$346.2M
Oct 2026
Priced at
—
Total raised
$97.3M
Last round
—

Who backs Highlightll Pharma?

11 investors
InvestorType
CICC CapitalPE / buyout
Hillhouse Investment GroupOther
Shenzhen Yifeng Investment Management EnterpriseVenture capital
Infinity GroupPE / buyout
Hankang CapitalVenture capital
Wuxi AstraZeneca CICC Venture Capital PartnershipOther
AIHC Capital Management—
Bayland Capital—
Huajin Venture Capital—
Kaitai Capital—
+ 1 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Highlightll Pharma investors

11 investors are on record for Highlightll Pharma, including CICC Capital, Hillhouse Investment Group, Shenzhen Yifeng Investment Management Enterprise and Infinity Group.

Free account
More of Highlightll Pharma with a free account
  • ·The complete investor list: 11 names
  • ·Watch Highlightll Pharma: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 11 firms already write checks for companies like Highlightll Pharma. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View